Modality
Small Molecule
MOA
EZH2i
Target
KRASG12D
Pathway
mTOR
ObesitySMAThymoma
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
Mar 2024
→ Nov 2027
Phase 1Current
NCT08880230
389 pts·SMA
2024-03→2027-11·Not yet recruiting
389 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-161.6y awayInterim· SMA
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2027-11-16 · 1.6y away
SMA
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08880230 | Phase 1 | SMA | Not yet recr... | 389 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |